References
1. Liu P, Wang L, Han D, Sun C, Xue X, Li G. Acquired long QT syndrome in chronic kidney disease patients. Ren Fail. 2020 Nov;42(1):54–65.
2. Patanè S, Marte F, Di Bella G, Currò A, Coglitore S. QT interval prolongation, torsade de pointes and renal disease. Vol. 130, International journal of cardiology. Netherlands; 2008. p. e71-3.
3. Alramly M, Darawad MW, Khalil AA. Slowing the progression of chronic kidney disease: comparison between predialysis and dialysis in Jordanian patients. Ren Fail. 2013;35(10):1348–52.
4. Familoni OB, Alebiosu CO, Ayodele OE. Effects and outcome of haemodialysis on QT intervals and QT dispersion in patients with chronic kidney disease. Cardiovasc J South Africa Off J South Africa Card Soc [and] South African Soc Card Pract. 2006;17(1):19–23.
5. Sherif KA, Abo-Salem E, Panikkath R, Nusrat M, Tuncel M. Cardiac repolarization abnormalities among patients with various stages of chronic kidney disease. Clin Cardiol. 2014 Jul;37(7):417–21.
6. Näppi SE, Virtanen VK, Saha HHT, Mustonen JT, Pasternack AI. QTc dispersion increases during hemodialysis with low-calcium dialysate. Kidney Int [Internet]. 2000 May 1;57(5):2117–22. Available from: https://doi.org/10.1046/j.1523-1755.2000.00062.x
7. Khosoosi Niaki MR, Saravi M, Oliaee F, Akbari R, Noorkhomami S, Bozorgi Rad SH, et al. Changes in QT interval before and after hemodialysis. Casp J Intern Med. 2013;4(1):590–4.
8. Oktavia D, Nasution SA, Setiati S. The clinical factors’ prediction of increased intradialytic QT dispersion on the electrocardiograms of chronic hemodialysis patients. Saudi J kidney Dis Transplant an Off Publ Saudi Cent Organ Transplantation, Saudi Arab. 2013 Mar;24(2):274–80.
9. Liu P, Han D, Sun X, Tan H, Wang Z, Liu C, et al. Prevalence and risk factors of acquired long QT syndrome in hospitalized patients with chronic kidney disease. J Investig Med Off Publ Am Fed Clin Res. 2019 Feb;67(2):289–94.
10. Gussak I, Gussak HM. Sudden cardiac death in nephrology: focus on acquired long QT syndrome. Nephrol Dial Transplant [Internet]. 2006;22(1):12–4. Available from: https://doi.org/10.1093/ndt/gfl587
11. Voroneanu L, Covic A. Arrhythmias in hemodialysis patients. J Nephrol. 2009;22(6):716–25.
12. Bignotto LH, Kallás ME, Djouki RJT, Sassaki MM, Voss GO, Soto CL, et al. Electrocardiographic findings in chronic hemodialysis patients. J Bras Nefrol ’orgao Of Soc Bras e Latino-Americana Nefrol. 2012;34(3):235–42.
13. Snitker S, Doerfler RM, Soliman EZ, Deo R, St Peter WL, Kramlik S, et al. Association of QT-Prolonging Medication Use in CKD with Electrocardiographic Manifestations. Clin J Am Soc Nephrol. 2017 Sep;12(9):1409–17.
14. Tisdale JE. Drug-induced QT interval prolongation and torsades de pointes: Role of the pharmacist in risk assessment, prevention and management. Can Pharm J (Ott). 2016 May;149(3):139–52.
15. The Hashemite Kingdom of Jordan Ministry of Health NDD. National Registry of End Stage Renal Disease Annual Report [Internet]. 2008. Available from: https://www.moh.gov.jo/
16. Khalil AA, Darawad M, Al Gamal E, Hamdan-Mansour AM, Abed MA. Predictors of dietary and fluid non-adherence in Jordanian patients with end-stage renal disease receiving haemodialysis: a cross-sectional study. J Clin Nurs. 2013 Jan;22(1–2):127–36.
17. Al-Azzam SI, Abu-Dahoud EY, El-Khatib HA, Dawoud TH, Al-Husein BA. Etiologies of chronic renal failure in Jordanian population. J Nephrol. 2007;20(3):336–9.
18. Al-Azayzih A, Gharaibeh S, Jarab AS, Mukattash TL. Prevalence of Torsades de Pointes inducing drugs usage among elderly outpatients in North Jordan Hospitals. Saudi Pharm J SPJ Off Publ Saudi Pharm Soc. 2018 Dec;26(8):1146–54.
19. Khalil AA, Abed MA, Ahmad M, Mansour AH. Under-diagnosed chronic kidney disease in Jordanian adults: prevalence and correlates. J Ren Care. 2018 Mar;44(1):12–8.
20. Al-Niemat SI, Aljbouri TM, Goussous LS, Efaishat RA, Salah RK. Antibiotic Prescribing Patterns in Outpatient Emergency Clinics at Queen Rania Al Abdullah II Children’s Hospital, Jordan, 2013. Oman Med J. 2014 Jul;29(4):250–4.
21. Otoom S, Batieha A, Hadidi H, Hasan M, Al Saudi K. Evaluation of drug use in Jordan using WHO prescribing indicators. EMHJ - Eastern Mediterranean Health Journal, 8 (4-5), 537-543, 2002. 2002. p. 537–43.
22. Ababneh MA, Al-Azzam SI, Ababneh R, Rababa’h AM, Demour S Al. Antibiotic prescribing for acute respiratory infections in children in Jordan. Int Health [Internet]. 2017;9(2):124–30. Available from: https://doi.org/10.1093/inthealth/ihx003
23. Al-Azzam SI, Alzoubi KH, Mhaidat NM, Haddadin RD, Masadeh MM, Tumah HN, et al. Preoperative antibiotic prophylaxis practice and guideline adherence in Jordan: a multi-centre study in Jordanian hospitals. J Infect Dev Ctries. 2012 Oct;6(10):715–20.
24. Zalloum N, Farha R, Awwad O, Samara N. Inappropriate prescribing of proton pump inhibitors among patients in two Jordanian tertiary health facilities. Trop J Pharm Res. 2016;15:1319–26.
25. Alqudah M, Al-Azzam S, Alzoubi K, Alkhatatbeh M, Rawashdeh N. Overuse of proton pump inhibitors for stress ulcer prophylaxis in Jordan. Int J Clin Pharmacol Ther. 2016;54.
26. Yasein N, Barghouti F, Irshaid Y, Suleiman A, Abu-Hassan D, Tawil R. Elderly Patients in Family Practice: Polypharmacy and Inappropriate Prescribing - Jordan. Int Med J. 2012;19.
27. AlQerem W, Jarrar Y, Alshaikh I, Madani A. The prevalence of drug-drug interactions and polypharmacy among elderly patients in Jordan. 2018;29.
28. Aburuz SM, Bulatova NR, Yousef A-MM, Al-Ghazawi MA, Alawwa IA, Al-Saleh A. Comprehensive assessment of treatment related problems in hospitalized medicine patients in Jordan. Int J Clin Pharm. 2011 Jun;33(3):501–11.
29. AbuRuz SM, Alrashdan Y, Jarab A, Jaber D, Alawwa IA. Evaluation of the impact of pharmaceutical care service on hospitalized patients with chronic kidney disease in Jordan. Int J Clin Pharm. 2013 Oct;35(5):780–9.
30. Hayes BD, Klein-Schwartz W, Barrueto F. Polypharmacy and the Geriatric Patient. Clin Geriatr Med. 2007;23(2):371–90.
31. Teixeira JJV, Crozatti MTL, dos Santos CA, Romano-Lieber NS. Potential Drug-Drug Interactions in Prescriptions to Patients over 45 Years of Age in Primary Care, Southern Brazil. PLoS One [Internet]. 2012;7(10):1–6. Available from: https://doi.org/10.1371/journal.pone.0047062
32. Patel VK, Acharya LD, Rajakannan T, Surulivelrajan M, Guddattu V, Padmakumar R. Potential drug interactions in patients admitted to cardiology wards of a south Indian teaching hospital. Australas Med J. 2011;4(1):9–14.
33. Assefa S, Mekonen Z. Potential Drug-Drug Interactions Among Adult Patients Admitted to Medical Wards at a Tertiary Teaching Hospital in Ethiopia. 2018;8:348–54.
34. Wilcock A, Charlesworth S, Twycross R, Waddington A, Worthington O, Murtagh FEM, et al. Prescribing Non-Opioid Drugs in End-Stage Kidney Disease. J Pain Symptom Manage [Internet]. 2017;54(5):776–87. Available from: http://www.sciencedirect.com/science/article/pii/S0885392417304190
35. McHugh ML. Interrater reliability: the kappa statistic. Biochem medica. 2012;22(3):276–82.
36. Rao JNK SA. On simple adjustments to chi-square tests with sample survey data. 1987;
37. Allen LaPointe NM, Curtis LH, Chan KA, Kramer JM, Lafata JE, Gurwitz JH, et al. Frequency of high-risk use of QT-prolonging medications. Pharmacoepidemiol Drug Saf [Internet]. 2006;15(6):361–8. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/pds.1155
38. Curtis LH, Østbye T, Sendersky V, Hutchison S, Allen LaPointe NM, Al-Khatib SM, et al. Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am J Med. 2003 Feb;114(2):135–41.
39. Moreno-Gutiérrez PA, Gaviria-Mendoza A, Cañón MM, Machado-Alba JE. High prevalence of risk factors in elderly patients using drugs associated with acquired torsades de pointes chronically in Colombia. Br J Clin Pharmacol. 2016 Aug;82(2):504–11.
40. Sarganas G, Garbe E, Klimpel A, Hering RC, Bronder E, Haverkamp W. Epidemiology of symptomatic drug-induced long QT syndrome and Torsade de Pointes in Germany. Eur Eur pacing, arrhythmias, Card Electrophysiol J Work groups Card pacing, arrhythmias, Card Cell Electrophysiol Eur Soc Cardiol. 2014 Jan;16(1):101–8.
41. Das B, Rawat VS, Ramasubbu SK, Kumar B. Frequency, characteristics and nature of risk factors associated with use of QT interval prolonging medications and related drug-drug interactions in a cohort of psychiatry patients. Therapie. 2019 Dec;74(6):599–609.
42. Danielsson B, Collin J, Jonasdottir Bergman G, Borg N, Salmi P, Fastbom J. Antidepressants and antipsychotics classified with torsades de pointes arrhythmia risk and mortality in older adults - a Swedish nationwide study. Br J Clin Pharmacol. 2016 Apr;81(4):773–83.
43. AlRuthia Y, Alkofide H, Alosaimi FD, Sales I, Alnasser A, Aldahash A, et al. Drug-drug interactions and pharmacists’ interventions among psychiatric patients in outpatient clinics of a teaching hospital in Saudi Arabia. Saudi Pharm J [Internet]. 2019;27(6):798–802. Available from: http://www.sciencedirect.com/science/article/pii/S1319016419300738
44. Ansari J. Drug interaction and pharmacist. J Young Pharm. 2010 Jul;2(3):326–31.
45. Shafiekhani M, Moosavi N, Firouzabadi D, Namazi S. Impact of Clinical Pharmacist’s Interventions on Potential Drug-Drug Interactions in the Cardiac Care Units of Two University Hospitals in Shiraz, South of Iran. J Res Pharm Pract. 2019;8(3):143–8.
46. Sommer J, Seeling A, Rupprecht H. Adverse Drug Events in Patients with Chronic Kidney Disease Associated with Multiple Drug Interactions and Polypharmacy. Drugs Aging. 2020 May;37(5):359–72.
47. Curtis LH, Østbye T, Sendersky V, Hutchison S, Dans PE, Wright A, et al. Inappropriate Prescribing for Elderly Americans in a Large Outpatient Population. Arch Intern Med [Internet]. 2004;164(15):1621–5. Available from: https://doi.org/10.1001/archinte.164.15.1621
Figure legends